Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SUBLOCADE ®safely and effectively. See full prescribing information for SUBLOCADE. SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use, CIII Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.
- generic_name
- buprenorphine
- product_names
- buprenorphine
- ndc
- 12496-0100, 12496-0300, 12496-0100-5, 12496-0100-2, 12496-0100-1, 12496-0300-5, 12496-0300-2, 12496-0300-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en